USA - engelsk - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - solaraze® (diclofenac sodium) gel is indicated for the topical treatment of actinic keratoses (ak). sun avoidance is indicated during therapy. solaraze® (diclofenac sodium) gel is contraindicated in patients with a known hypersensitivity to diclofenac, benzyl alcohol, polyethylene glycol monomethyl ether 350 and/or hyaluronate sodium. solaraze® (diclofenac sodium) gel is contraindicated in the following patients: - in the setting of coronary artery bypass graft (cabg) surgery.

USA - engelsk - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - temovate® cream and ointment are super-high potency corticos-teroid formulations indicated for the relief of the inflammatory and pru-ritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. temovate® (clobetasol propionate cream and ointment) cream and ointment, 0.05% are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

USA - engelsk - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 30 mg in 1 g - solaraze® (diclofenac sodium) gel is indicated for the topical treatment of actinic keratoses (ak). sun avoidance is indicated during therapy. solaraze® (diclofenac sodium) gel is contraindicated in patients with a known hypersensitivity to diclofenac, benzyl alcohol, polyethylene glycol monomethyl ether 350 and/or hyaluronate sodium. solaraze® (diclofenac sodium) gel is contraindicated in the following patients: - in the setting of coronary artery bypass graft (cabg) surgery.

USA - engelsk - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - oxiconazole nitrate (unii: rq8ul4c17s) (oxiconazole - unii:c668q9i33j) - oxiconazole 10 mg in 1 g - oxistat® cream and lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes, or epidermophyton floccosum. oxistat® cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to malassezia furfur (see dosage and administration and clinical studies). oxistat® cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which oxistat® cream has been shown to be effective rarely occur in children below the age of 12. oxistat® cream and lotion are contraindicated in individuals who have shown hypersensitivity to any of their components.

USA - engelsk - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - cutivate® cream is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. cutivate® cream may be used with caution in pediatric patients 3 months of age or older. the safety and efficacy of drug use for longer than 4 weeks in this population have not been established. the safety and efficacy of cutivate® cream in pediatric patients below 3 months of age have not been established. cutivate® cream is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.

USA - engelsk - NLM (National Library of Medicine)

pharmaderm, a division of fougera pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - temovate® scalp application is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 ml/week because of the potential for the drug to suppress the hpa axis. this product is not recommended for use in pediatric patients under 12 years of age. temovate® scalp application is contraindicated in patients with primary infections of the scalp, or in patients who are hypersensitive to clobetasol propionate, other corticosteroids, or any ingredient in this preparation.

USA - engelsk - NLM (National Library of Medicine)

pharmaderm, a division of fougera pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - temovate® gel is a super-high potency cor-ticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. temovate® gel is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

USA - engelsk - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - diflorasone diacetate (unii: 7w2j09scwx) (diflorasone - unii:t2dhj9645w) - diflorasone diacetate 0.5 mg in 1 g - topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

USA - engelsk - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 0.05 mg in 1 g - pregnancy category c

USA - engelsk - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate 0.5 mg in 1 g - temovate® e is a super-high potency corticosteroid indicated for: temovate® e is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age and older. treatment should be limited to 2 consecutive weeks, and the total dosage should not exceed 50 grams per week. temovate® e is indicated for the topical treatment of moderate to severe plaque-type psoriasis. treatment beyond 4 consecutive weeks is not recommended. use in pediatric patients under 16 years of age is not recommended. temovate® e should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. the total dosage should not exceed 50 grams per week. avoid use if skin atrophy is present at the treatment site. none pregnancy category c. there are no adequate and well-controlled studies in pregnant women. therefore, temovate® e should be used during pregnancy only if the